What is Acadia Healthcare Company, Inc.'s earnings per share (EPS)?

Acadia Healthcare Company, Inc. (ACHC) reported diluted earnings per share of -$12.16 for fiscal year 2025. This represents a -537.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acadia Healthcare Company, Inc. (ACHC) Financials

ACHC

Trailing 12 months to March 31, 2026

Revenue $3.4B +6.8% YoY

Net Income -$1.1B -690.1% YoY

EPS (Diluted) -$12.20 -698.0% YoY

Free Cash Flow -$291.8M -12.2% YoY

Market Cap $2.8B as of Oct 14, 2026

Price / Sales 0.8x on $3.4B revenue, trailing 12 months to March 31, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to March 31, 2026

Price / Book 1.4x on $2.0B equity, Q1 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Apr 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed Apr 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACHC SEC filings page.

Acadia Healthcare Company, Inc. (ACHC) reported $3.4B in revenue over the twelve months to Mar 31, 2026, up 6.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACHC FY2025 2026-10-03

The business still produces operating cash, but heavy reinvestment and a 2025 balance-sheet reset now dominate reported earnings.

In FY2025, a net loss of $1.10B coexisted with operating cash flow of $132M, so the accounting collapse was not a matching cash-flow collapse. Instead, capital spending of $572M pushed free cash flow to -$440M, showing that cash generation is being absorbed by reinvestment rather than accumulating on the balance sheet.

FY2024 combined $690M of capital spending with free cash flow of -$561M. FY2025 reduced spending to $572M but still posted -$440M, indicating that capital intensity remains a recurring constraint even when operations generate cash.

Debt-to-equity more than doubled from 0.5x in FY2023 to 1.3x in FY2025, indicating a materially more leveraged capital structure. Equity fell from $3.07B to $1.95B, so the higher leverage reflects a thinner capital cushion, not debt alone.

Financial Health Signals

Financial Health Score 25/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Acadia Healthcare Company, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Acadia Healthcare Company, Inc., and counted as zero in the overall score.

Growth

Acadia Healthcare Company, Inc.'s revenue grew 5.0% year-over-year to $3.3B, a solid pace of expansion. This earns a growth score of 55/100.

Leverage

Acadia Healthcare Company, Inc. has a moderate D/E ratio of 1.27. This balance of debt and equity financing earns a leverage score of 42/100.

Liquidity

Acadia Healthcare Company, Inc.'s current ratio of 1.55 indicates adequate short-term liquidity, earning a score of 43/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Acadia Healthcare Company, Inc. generated $131.9M in operating cash flow, capex of $571.8M consumed most of it, leaving -$439.9M in free cash flow. This results in a low score of 11/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Not available for Acadia Healthcare Company, Inc., and counted as zero in the overall score.

Piotroski F-Score Partial

5/8

Acadia Healthcare Company, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Acadia Healthcare Company, Inc. reported a net loss of $1.1B while generating $131.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$828.8M

YoY+7.6%

QoQ+0.9%

5Y CAGR+8.5%

Acadia Healthcare Company, Inc. generated $828.8M in revenue in Q1 2026. This represents an increase of 7.6% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Net Income

$4.1M

YoY-51.0%

QoQ+100.3%

5Y CAGR-15.8%

10Y CAGR-16.8%

Acadia Healthcare Company, Inc. reported $4.1M in net income in Q1 2026. This represents a decrease of 51.0% from the same quarter a year earlier. Against the prior quarter it is up 100.3%.

EPS (Diluted)

$0.05

YoY-44.4%

QoQ+100.4%

5Y CAGR-14.6%

10Y CAGR-16.7%

Acadia Healthcare Company, Inc. earned $0.05 per diluted share (EPS) in Q1 2026. This represents a decrease of 44.4% from the same quarter a year earlier. Against the prior quarter it is up 100.4%.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Free Cash Flow

-$15.0M

YoY+90.8%

QoQ+91.6%

Acadia Healthcare Company, Inc. recorded an outflow of $15.0M in free cash flow in Q1 2026, representing a cash shortfall after capex. This represents an increase of 90.8% from the same quarter a year earlier. Against the prior quarter it is up 91.6%.

Cash & Debt

$158.5M

YoY+73.7%

QoQ+18.9%

5Y CAGR-2.4%

10Y CAGR+15.8%

Acadia Healthcare Company, Inc. held $158.5M in cash against $2.5B in long-term debt as of Q1 2026.

Shares Outstanding

Diluted avg 91M

Acadia Healthcare Company, Inc. had a weighted average of 91M diluted shares in Q1 2026; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Net Margin

0.5%

YoY-0.6pp

5Y change-1.3pp

Acadia Healthcare Company, Inc.'s net profit margin was 0.5% in Q1 2026, showing the share of revenue converted to profit. This is down 0.6 percentage points from the same quarter a year earlier.

Return on Equity

0.2%

YoY-0.1pp

QoQ+60.6pp

5Y change-0.2pp

10Y change-0.8pp

Acadia Healthcare Company, Inc.'s ROE was 0.2% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 60.6 percentage points.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Capital Allocation

Capital Expenditures

$76.6M

YoY-56.2%

QoQ-17.8%

5Y CAGR+5.5%

10Y CAGR-1.6%

Acadia Healthcare Company, Inc. invested $76.6M in capex in Q1 2026, funding long-term assets and infrastructure. This represents a decrease of 56.2% from the same quarter a year earlier. Against the prior quarter it is down 17.8%.

R&D Spending

Not reported for Q1 2026.

Share Buybacks

Not reported for Q1 2026.

ACHC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACHC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.4B	$3.3B+5.0%	$3.2B+7.7%	$2.9B+12.2%	$2.6B+12.8%	$2.3B+10.7%	$2.1B+4.1%	$2.0B+5.4%	$1.9B-32.8%	$2.8B+0.9%	$2.8B	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$199.4M	$177.6M+13.3%	$156.8M+2.3%	$153.3M+23.3%	$124.3M+14.9%	$108.2M+10.6%	$97.8M+8.2%	$90.4M+4.4%	$86.6M+13.4%	$76.4M-12.0%	$86.8M+27.1%	$68.3M+85.1%	$36.9M+27.2%	$29.0M+34.3%	$21.6M+64.9%	$13.1M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$585.9M-1.3%	$593.6M-1.8%	$604.4M-0.7%	$608.6M+50.3%	$404.8M+87.9%	$215.5M+48.3%	$145.3M+79.5%	$81.0M	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$673.8M0.0%	$673.9M-9.8%	$747.4M+0.5%	$743.7M+58.8%	$468.4M+88.7%	$248.2M+52.8%	$162.4M+82.6%	$88.9M	N/A
Interest Expense	-$148.0M	-$138.9M-19.3%	-$116.4M-41.7%	-$82.1M-17.7%	-$69.8M+9.4%	-$77.0M+51.3%	-$158.1M+15.6%	-$187.3M-1.5%	-$184.5M-4.8%	-$176.0M+2.9%	-$181.3M-69.9%	-$106.7M-121.4%	-$48.2M-29.5%	-$37.3M-225.1%	$29.8M+223.9%	$9.2M
Income Tax	$28.1M	$26.0M-66.4%	$77.4M+898.0%	-$9.7M-110.3%	$94.1M+39.3%	$67.6M+66.4%	$40.6M+61.9%	$25.1M+153.2%	$9.9M-73.4%	$37.2M+29.3%	$28.8M-46.1%	$53.4M+24.4%	$42.9M+65.2%	$26.0M+110.8%	$12.3M+333.8%	-$5.3M
Net Income	-$1.1B	-$1.1B-531.4%	$255.6M+1279.7%	-$21.7M-107.9%	$273.1M+43.3%	$190.6M+128.4%	-$672.1M-717.1%	$108.9M+162.0%	-$175.8M-187.9%	$199.8M+3153.1%	$6.1M-94.5%	$112.6M+35.5%	$83.0M+95.0%	$42.6M+108.7%	$20.4M+158.5%	-$34.9M
EPS (Basic)	N/A	-$12.16-535.8%	$2.79+1262.5%	-$0.24-107.9%	$3.05+41.9%	$2.15+128.1%	-$7.65-716.9%	$1.24+161.7%	-$2.01-187.4%	$2.30+3185.7%	$0.07-95.8%	$1.65+9.3%	$1.51+77.6%	$0.85+60.4%	$0.53+128.5%	-$1.86
EPS (Diluted)	-$12.20	-$12.16-537.4%	$2.78+1258.3%	-$0.24-108.1%	$2.98+41.9%	$2.10+127.7%	-$7.59-712.1%	$1.24+161.7%	-$2.01-187.4%	$2.30+3185.7%	$0.07-95.7%	$1.64+9.3%	$1.50+76.5%	$0.85+60.4%	$0.53	-$1.86
Diluted Shares (Avg)	N/A	91M-1.5%	92M+1.2%	91M-0.7%	92M+0.8%	91M+2.5%	89M+0.9%	88M+0.5%	87M+0.4%	87M+1.3%	86M+25.7%	68M+23.6%	55M+10.1%	50M+29.9%	39M	19M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Revenue	$828.8M+7.6%	$821.5M+6.1%	$851.6M+4.4%	$869.2M+9.2%	$770.5M+0.3%	$774.2M+4.2%	$815.6M+8.7%	$796.0M+8.8%
SG&A Expenses	$467.0M+4.9%	-$1.2B-6.6%	$462.2M+7.9%	$452.4M+7.8%	$445.3M+6.6%	-$1.1B-8.8%	$428.1M+8.6%	$419.8M+8.6%
Interest Expense	-$38.3M-31.3%	-$37.9M-26.1%	-$36.6M-22.4%	-$35.1M-20.5%	-$29.2M-7.2%	-$30.1M-46.9%	-$29.9M-44.3%	-$29.2M-39.5%
Income Tax	$6.5M+47.6%	$7.8M+75.1%	$1.7M-93.9%	$12.1M-52.9%	$4.4M-78.1%	$4.5M-77.8%	$27.2M+137.8%	$25.6M+12.1%
Net Income	$4.1M-51.0%	-$1.2B-3710.4%	$36.2M-46.8%	$30.1M-61.6%	$8.4M-89.0%	$32.6M-43.5%	$68.1M+131.3%	$78.5M+8.6%
EPS (Basic)	$0.05-44.4%	-$12.98-3808.6%	$0.40-45.9%	$0.33-61.6%	$0.09-89.3%	$0.35-44.4%	$0.74+131.0%	$0.86+8.9%
EPS (Diluted)	$0.05-44.4%	-$12.98-3705.6%	$0.40-45.9%	$0.33-61.2%	$0.09-89.2%	$0.36-42.9%	$0.74+131.0%	$0.85+7.6%
Diluted Shares (Avg)	91M-1.3%	N/A	91M-1.7%	90M-1.7%	92M0.0%	N/A	92M+1.1%	92M+0.5%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA.

ACHC Balance Sheet

ACHC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$5.5B-7.2%	$6.0B+11.2%	$5.4B+7.4%	$5.0B+4.6%	$4.8B-26.6%	$6.5B-5.5%	$6.9B+11.4%	$6.2B-3.9%	$6.4B+6.6%	$6.0B+40.8%	$4.3B+93.9%	$2.2B+80.2%	$1.2B+24.5%	$983.4M+138.1%	$413.0M
Current Assets	$814.1M+41.0%	$577.5M-3.1%	$596.0M+17.8%	$506.1M+2.2%	$495.0M-80.4%	$2.5B+365.4%	$542.2M+20.4%	$450.4M-4.5%	$471.6M+10.2%	$427.9M+45.2%	$294.7M+7.5%	$274.1M+88.9%	$145.1M+2.9%	$141.0M+25.2%	$112.6M
Cash & Equivalents	$133.2M+74.6%	$76.3M-23.8%	$100.1M+2.5%	$97.6M-27.0%	$133.8M-64.7%	$378.7M+280.5%	$99.5M+97.1%	$50.5M-24.9%	$67.3M+17.9%	$57.1M+408.8%	$11.2M-88.1%	$94.0M+1958.2%	$4.6M-90.8%	$49.4M-19.2%	$61.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$5.7M+0.6%	$5.7M+6.7%	$5.3M+4.2%	$5.1M+6.3%	$4.8M-1.3%	$4.9M+19.0%	$4.1M-19.4%	$5.1M+5.6%	$4.8M+3.3%	$4.6M-1.0%	$4.7M+44.1%	$3.2M	N/A	N/A	N/A
Accounts Receivable	$440.6M+20.6%	$365.3M+1.1%	$361.5M+12.1%	$322.4M+14.6%	$281.3M+2.8%	$273.6M-5.3%	$288.9M-9.2%	$318.1M+7.1%	$296.9M+12.8%	$263.3M+21.6%	$216.6M+83.0%	$118.4M+23.5%	$95.9M+50.1%	$63.9M+81.8%	$35.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.3B-42.8%	$2.3B+1.7%	$2.2B+0.1%	$2.2B+1.0%	$2.2B+4.5%	$2.1B+1.0%	$2.1B+2.0%	$2.0B-25.7%	$2.8B+2.6%	$2.7B+26.0%	$2.1B+165.0%	$803.0M+21.4%	$661.5M+18.7%	$557.4M+198.4%	$186.8M
Total Liabilities	$3.4B+22.4%	$2.8B+11.9%	$2.5B+18.4%	$2.1B-4.5%	$2.2B-51.9%	$4.5B+4.7%	$4.3B+13.9%	$3.8B-0.5%	$3.8B-0.3%	$3.8B+48.3%	$2.6B+95.2%	$1.3B+78.2%	$743.9M+35.1%	$550.9M+74.0%	$316.6M
Current Liabilities	$525.2M-9.1%	$577.9M-34.8%	$885.8M+128.1%	$388.3M-4.1%	$404.9M-69.1%	$1.3B+182.2%	$463.6M+11.3%	$416.4M+10.3%	$377.4M+10.1%	$342.9M+18.1%	$290.2M+74.9%	$165.9M+44.7%	$114.7M+59.6%	$71.9M+76.7%	$40.7M
Non-Current Liabilities	$2.9B+30.8%	$2.2B+38.0%	$1.6B-6.7%	$1.7B-4.6%	$1.8B-45.0%	$3.2B-16.5%	$3.9B+14.2%	$3.4B-1.7%	$3.5B-1.3%	$3.5B+52.2%	$2.3B+98.1%	$1.2B+84.4%	$629.3M+31.4%	$479.0M+73.6%	$276.0M
Long-Term Debt	$2.5B+31.5%	$1.9B+40.0%	$1.3B-1.6%	$1.4B-7.7%	$1.5B-50.2%	$3.0B-4.4%	$3.1B-1.7%	$3.2B-1.4%	$3.2B-1.5%	$3.3B+48.2%	$2.2B+108.6%	$1.1B+74.9%	$601.9M+29.3%	$465.6M+72.0%	$270.7M
Total Equity	$1.9B-36.6%	$3.1B+10.5%	$2.8B-1.1%	$2.8B+11.7%	$2.5B+32.5%	$1.9B-24.2%	$2.5B+7.4%	$2.3B-9.3%	$2.6B+18.7%	$2.2B+28.8%	$1.7B+91.0%	$881.0M+83.3%	$480.7M+11.1%	$432.6M+348.9%	$96.4M
Retained Earnings	-$765.8M-297.7%	$387.3M+194.1%	$131.7M-14.1%	$153.4M+228.1%	-$119.8M+61.4%	-$310.4M-185.8%	$361.7M+43.1%	$252.8M-41.0%	$428.6M+94.7%	$220.1M+2.9%	$214.0M+111.0%	$101.4M+451.3%	$18.4M+176.1%	-$24.2M+45.8%	-$44.6M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Total Assets	$5.5B-9.8%	$5.5B-7.2%	$6.4B+9.2%	$6.3B+11.1%	$6.1B+11.4%	$6.0B+11.2%	$5.9B+9.8%	$5.7B+10.2%
Current Assets	$837.2M+31.0%	$814.1M+41.0%	$748.0M+14.7%	$691.6M+7.2%	$639.0M+4.6%	$577.5M-3.1%	$652.1M-7.3%	$645.2M+11.5%
Cash & Equivalents	$158.5M+73.7%	$133.2M+74.6%	$118.7M+44.5%	$131.4M+70.3%	$91.2M+18.0%	$76.3M-23.8%	$82.1M-17.5%	$77.2M-31.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$5.9M+3.9%	$5.7M+0.6%	$6.2M+13.3%	$5.8M-2.9%	$5.7M-0.6%	$5.7M+6.7%	$5.5M+0.7%	$6.0M+10.1%
Accounts Receivable	$471.8M+18.9%	$440.6M+20.6%	$430.8M+12.2%	$408.5M+4.9%	$396.6M+2.7%	$365.3M+1.1%	$383.9M+5.9%	$389.4M+12.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.3B-42.8%	$1.3B-42.8%	$2.3B+1.0%	$2.3B+0.7%	$2.3B+0.7%	$2.3B+1.7%	$2.3B+1.7%	$2.3B+1.7%
Total Liabilities	$3.4B+13.6%	$3.4B+22.4%	$3.1B+14.6%	$3.1B+18.0%	$3.0B+17.0%	$2.8B+11.9%	$2.7B+7.4%	$2.6B+22.2%
Current Liabilities	$489.4M+3.4%	$525.2M-9.1%	$517.9M-15.0%	$523.7M-4.2%	$473.4M-1.9%	$577.9M-34.8%	$609.5M-29.5%	$546.5M+26.4%
Non-Current Liabilities	$2.9B+15.5%	$2.9B+30.8%	$2.6B+23.2%	$2.6B+23.9%	$2.5B+21.4%	$2.2B+38.0%	$2.1B+26.6%	$2.1B+21.1%
Long-Term Debt	$2.5B+14.2%	$2.5B+31.5%	$2.3B+26.6%	$2.2B+26.6%	$2.2B+21.7%	$1.9B+40.0%	$1.8B+33.7%	$1.8B+29.3%
Total Equity	$2.0B-35.6%	$1.9B-36.6%	$3.1B+2.9%	$3.1B+4.2%	$3.0B+6.1%	$3.1B+10.5%	$3.0B+11.8%	$3.0B+1.1%
Retained Earnings	-$761.7M-318.6%	-$765.8M-297.7%	$411.7M+16.1%	$375.4M+31.0%	$348.5M+67.4%	$387.3M+194.1%	$354.7M+379.4%	$286.6M-1.8%

ACHC Cash Flow Statement

ACHC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$182.0M	$131.9M+1.7%	$129.7M-71.9%	$462.3M+21.5%	$380.6M+1.6%	$374.5M-43.2%	$658.8M+97.9%	$332.9M-19.6%	$414.1M+3.6%	$399.6M+10.5%	$361.5M+50.4%	$240.4M+108.5%	$115.3M+75.8%	$65.6M+93.4%	$33.9M+264.0%	-$20.7M
Depreciation & Amortization	N/A	$189.2M+26.5%	$149.6M+13.0%	$132.3M+12.4%	$117.8M+10.4%	$106.7M+12.0%	$95.3M+8.3%	$87.9M+9.4%	$80.3M-43.8%	$143.0M+5.9%	$135.1M+112.6%	$63.5M+94.5%	$32.7M+91.1%	$17.1M+114.1%	$8.0M+86.6%	$4.3M
Stock-Based Compensation	N/A	$31.7M-14.6%	$37.1M+14.9%	$32.3M+9.0%	$29.6M-21.0%	$37.5M+66.8%	$22.5M+30.0%	$17.3M-21.3%	$22.0M-6.2%	$23.5M-17.2%	$28.3M+38.5%	$20.5M+103.5%	$10.1M+91.6%	$5.2M+131.5%	$2.3M-86.9%	$17.3M
Capital Expenditures	$473.7M	$571.8M-17.2%	$690.4M+62.8%	$424.1M+43.2%	$296.1M+21.0%	$244.8M+8.8%	$225.0M-3.3%	$232.7M-8.1%	$253.2M-7.7%	$274.2M-10.8%	$307.5M+11.4%	$276.0M+143.8%	$113.2M+64.3%	$68.9M+149.8%	$27.6M+188.7%	$9.6M
Free Cash Flow	-$291.8M	-$439.9M+21.5%	-$560.7M-1567.5%	$38.2M-54.7%	$84.4M-34.9%	$129.7M-70.1%	$433.8M+332.9%	$100.2M-37.7%	$160.9M+28.3%	$125.4M+132.2%	$54.0M+251.5%	-$35.6M-1845.5%	$2.0M+160.4%	-$3.4M-153.6%	$6.3M+120.9%	-$30.2M
Investing Cash Flow	-$433.2M	-$556.2M+24.5%	-$736.5M-85.4%	-$397.2M-29.9%	-$305.8M-130.2%	$1.0B+459.5%	-$281.8M-40.1%	-$201.1M+44.3%	-$361.0M-7.3%	-$336.5M+49.0%	-$660.4M	N/A	-$860.8M-254.3%	-$243.0M+53.7%	-$524.6M-132.6%	-$225.6M
Financing Cash Flow	$318.5M	$481.3M-17.5%	$583.0M+1029.9%	-$62.7M+43.5%	-$110.9M+93.2%	-$1.6B-3077.8%	-$51.5M+16.4%	-$61.6M+8.5%	-$67.3M-12.1%	-$60.1M-116.7%	$358.8M	N/A	$838.0M+532.0%	$132.6M-72.3%	$479.0M+60.3%	$298.7M
Share Buybacks	N/A	$50.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$61.5M+436.1%	-$86.3M-173.9%	$73.2M-55.1%	$133.5M-22.0%	$11.5M+103.6%	$116.7M+0.3%	$163.1M+18.3%	$171.1M+4.5%
Depreciation & Amortization	$52.4M+11.5%	$45.8M+15.7%	$47.5M+26.1%	$49.0M+35.8%	$47.0M+29.4%	$39.5M+11.8%	$37.6M+12.7%	$36.1M+12.7%
Stock-Based Compensation	$8.0M-8.3%	N/A	$6.0M-36.3%	$10.5M+18.9%	$8.7M0.0%	N/A	$9.5M+16.0%	$8.9M+20.7%
Capital Expenditures	$76.6M-56.2%	$93.2M-54.2%	$136.2M-28.4%	$167.7M+8.8%	$174.6M+22.6%	$203.5M+46.7%	$190.2M+48.6%	$154.2M+69.8%
Free Cash Flow	-$15.0M+90.8%	-$179.5M-106.8%	-$63.0M-132.5%	-$34.2M-302.5%	-$163.2M+64.8%	-$86.8M-287.1%	-$27.1M-376.4%	$16.9M-76.8%
Investing Cash Flow	-$60.2M+67.1%	-$92.4M+54.5%	-$129.8M+32.8%	-$150.8M+3.0%	-$183.2M+0.7%	-$203.3M-84.6%	-$193.1M-49.2%	-$155.5M-71.3%
Financing Cash Flow	$23.9M-87.2%	$193.3M+139.2%	$43.8M+25.6%	$57.5M+463.7%	$186.7M-61.4%	$80.8M+1528.9%	$34.9M+265.7%	-$15.8M+35.9%
Share Buybacks	N/A	$0	$0	$3.2M	$46.9M	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

ACHC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACHC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	29.2%-2.0pp	31.2%+9.8pp	21.3%-0.3pp	21.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	-33.3%-41.4pp	8.1%+8.8pp	-0.7%-11.2pp	10.5%+2.2pp	8.2%+40.4pp	-32.2%-37.6pp	5.4%+14.6pp	-9.2%-16.3pp	7.0%+6.8pp	0.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-56.6%-64.9pp	8.3%+9.1pp	-0.8%-10.5pp	9.7%+2.1pp	7.6%+43.0pp	-35.4%-39.7pp	4.3%+11.9pp	-7.5%-15.3pp	7.8%+7.5pp	0.3%-6.4pp	6.7%-2.7pp	9.4%+0.6pp	8.9%+4.1pp	4.7%+40.9pp	-36.2%
Return on Assets	-20.0%-24.2pp	4.3%+4.7pp	-0.4%-5.9pp	5.5%+1.5pp	4.0%+14.3pp	-10.3%-11.9pp	1.6%+4.4pp	-2.9%-6.0pp	3.1%+3.0pp	0.1%-2.5pp	2.6%-1.1pp	3.8%+0.3pp	3.5%+1.4pp	2.1%+10.5pp	-8.5%
Current Ratio	1.55+0.6x	1.00+0.3x	0.67-0.6x	1.30+0.1x	1.22-0.7x	1.93+0.8x	1.17+0.1x	1.08-0.2x	1.250.0x	1.25+0.2x	1.02-0.6x	1.65+0.4x	1.27-0.7x	1.96-0.8x	2.77
Debt-to-Equity	1.27+0.7x	0.61+0.1x	0.480.0x	0.49-0.1x	0.59-1.0x	1.56+0.3x	1.24-0.1x	1.35+0.1x	1.25-0.3x	1.50+0.2x	1.30+0.1x	1.19-0.1x	1.25+0.2x	1.08-1.7x	2.81
Asset Turnover	0.60+0.1x	0.530.0x	0.550.0x	0.520.0x	0.49+0.2x	0.320.0x	0.290.0x	0.31-0.1x	0.440.0x	0.47	N/A	N/A	N/A	N/A	N/A
FCF Margin	-13.3%+4.5pp	-17.8%-19.1pp	1.3%-1.9pp	3.2%-2.4pp	5.6%-15.2pp	20.8%+15.8pp	5.0%-3.5pp	8.5%+4.0pp	4.4%+2.5pp	1.9%	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Net Margin	0.5%-0.6pp	-143.3%	4.3%-4.1pp	3.5%-6.4pp	1.1%-8.9pp	4.2%-3.6pp	8.3%+37.4pp	9.9%0.0pp
Return on Equity	0.2%-0.1pp	-60.4%-61.5pp	1.2%-1.1pp	1.0%-1.7pp	0.3%-2.4pp	1.1%-1.0pp	2.3%+10.3pp	2.7%+0.2pp
Return on Assets	0.1%-0.1pp	-21.3%-21.9pp	0.6%-0.6pp	0.5%-0.9pp	0.1%-1.2pp	0.5%-0.5pp	1.2%+5.2pp	1.4%0.0pp
Current Ratio	1.71+0.4x	1.55+0.6x	1.44+0.4x	1.32+0.1x	1.35+0.1x	1.00+0.3x	1.07+0.3x	1.18-0.2x
Debt-to-Equity	1.27+0.6x	1.27+0.7x	0.73+0.1x	0.73+0.1x	0.72+0.1x	0.61+0.1x	0.60+0.1x	0.60+0.1x
Asset Turnover	0.150.0x	0.150.0x	0.130.0x	0.140.0x	0.130.0x	0.130.0x	0.140.0x	0.140.0x
FCF Margin	-1.8%+19.4pp	-21.9%-10.6pp	-7.4%-4.1pp	-3.9%-6.1pp	-21.2%+39.2pp	-11.2%-8.2pp	-3.3%-4.6pp	2.1%-7.8pp

Not reported in any period shown, so not listed: Gross Margin, Operating Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Acadia Healthcare Company, Inc. ACHC	FY2025	$3.3B	-$1.1B	-33.3%	$2.8B	25/100
LifeStance Health Group, Inc. LFST	FY2025	$1.4B	$9.7M	0.7%	$4.7B	51/100
Addus HomeCare Corp. ADUS	FY2025	$1.4B	$95.9M	6.7%	$2.1B	68/100
Surgery Partners, Inc. SGRY	FY2025	$3.3B	-$77.9M	-2.4%	$1.9B	54/100
Concentra Group Holdings Parent, Inc. CON	FY2025	$2.2B	$166.4M	7.7%	$4.8B	57/100

Where Acadia Healthcare Company, Inc. Ranks

Frequently Asked Questions

What is Acadia Healthcare Company, Inc.'s annual revenue?

Acadia Healthcare Company, Inc. (ACHC) reported $3.3B in total revenue for fiscal year 2025. This represents a 5.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Acadia Healthcare Company, Inc.'s revenue growing?

Acadia Healthcare Company, Inc. (ACHC) revenue grew by 5.0% year-over-year, from $3.2B to $3.3B in fiscal year 2025.

Is Acadia Healthcare Company, Inc. profitable?

No, Acadia Healthcare Company, Inc. (ACHC) reported a net income of -$1.1B in fiscal year 2025, with a net profit margin of -33.3%.

How much debt does Acadia Healthcare Company, Inc. have?

As of fiscal year 2025, Acadia Healthcare Company, Inc. (ACHC) had $133.2M in cash and equivalents against $2.5B in long-term debt.

What is Acadia Healthcare Company, Inc.'s net profit margin?

Acadia Healthcare Company, Inc. (ACHC) had a net profit margin of -33.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Acadia Healthcare Company, Inc.'s return on equity (ROE)?

Acadia Healthcare Company, Inc. (ACHC) has a return on equity of -56.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Acadia Healthcare Company, Inc.'s free cash flow?

Acadia Healthcare Company, Inc. (ACHC) recorded an outflow of $439.9M in free cash flow during fiscal year 2025. This represents a 21.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Acadia Healthcare Company, Inc.'s operating cash flow?

Acadia Healthcare Company, Inc. (ACHC) generated $131.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Acadia Healthcare Company, Inc.'s total assets?

Acadia Healthcare Company, Inc. (ACHC) had $5.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Acadia Healthcare Company, Inc.'s capital expenditures?

Acadia Healthcare Company, Inc. (ACHC) invested $571.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Acadia Healthcare Company, Inc. buy back shares?

Yes, Acadia Healthcare Company, Inc. (ACHC) spent $50.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Acadia Healthcare Company, Inc. have outstanding?

Acadia Healthcare Company, Inc. (ACHC) had 92M shares outstanding as of fiscal year 2025.

What is Acadia Healthcare Company, Inc.'s current ratio?

Acadia Healthcare Company, Inc. (ACHC) had a current ratio of 1.55 as of fiscal year 2025, which is generally considered healthy.

What is Acadia Healthcare Company, Inc.'s debt-to-equity ratio?

Acadia Healthcare Company, Inc. (ACHC) had a debt-to-equity ratio of 1.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Acadia Healthcare Company, Inc.'s return on assets (ROA)?

Acadia Healthcare Company, Inc. (ACHC) had a return on assets of -20.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Acadia Healthcare Company, Inc.'s P/E ratio?

Acadia Healthcare Company, Inc. (ACHC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2026). The market capitalization is $2.8B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Acadia Healthcare Company, Inc.'s price-to-sales ratio?

Acadia Healthcare Company, Inc. (ACHC) trades at 0.8x sales, its market capitalization divided by revenue of $3.4B revenue, trailing 12 months to March 31, 2026. The market capitalization is $2.8B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Acadia Healthcare Company, Inc.'s Piotroski F-Score?

Acadia Healthcare Company, Inc. (ACHC) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Acadia Healthcare Company, Inc.'s earnings high quality?

Acadia Healthcare Company, Inc. (ACHC) reported a net loss of $1.1B while generating $131.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Acadia Healthcare Company, Inc.?

Acadia Healthcare Company, Inc. (ACHC) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.